rheumatic%20fever%20-%20acute
RHEUMATIC FEVER - ACUTE
Acute rheumatic fever is an autoimmune response to a previous group A beta-hemolytic streptococcal (GAS) infection causing acute generalized anti-inflammatory response primarily affecting the heart.
It often presents in patients 5-14 years of age and uncommon before 3 years and after 21 years of age.
Patients presenting with acute rheumatic fever are severely unwell, in extreme pain and requires hospitalization.

Rheumatic Fever - Acute Drug Information

Drug Information

Indication: Relief of mild to moderate pain & fever.

Indication: Short-term treatment of upper & lower resp tract, skin & soft tissue, GUT infections. Tab & inj Sh...

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Oral: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; acu...

Indication: HTN. Adjunct to digitalis &/or diuretic therapy in CHF.

Actimol Menstrual
pamabrom + paracetamol

Indication: Symptomatic relief of bloating, water-wt gain, backache, muscular aches, pre-menstrual & menstrual discomf...

Alka-Seltzer
aspirin + citric acid + sodium bicarbonate

Indication: Relief of headache & upset stomach. Fever, colds & flu discomfort, muscular aches & pains.

Indication: Infections due to gm -ve & +ve organisms & non-penicillinase-producing staph.

Indication: Mild to moderate pain & fever.

Indication: Resp tract, ENT, O&G, skin & soft tissue, bone & dental infections, UTI. Prophylaxis of recurrent ...

1  /  18
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.
Audrey Abella, 16 Sep 2020
The final results of EVAPORATE* reinforce the plaque-regressing potential of icosapent ethyl (IPE) in patients on statins for elevated triglycerides.